Johnson & Johnson (JNJ)

Selling surgical robots is not the largest source of Intuitive Surgical's revenue.

Medtronic grew revenue by 14% in the first quarter of its fiscal 2027.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Instead of trying to pick stocks like Warren Buffett, follow his advice and buy this S&P 500 ETF.

With just two days to go, these Dividend Kings with attractive yields could be just what you are looking for in October.

Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

Intuitive Surgical posted Q3 margin impairments from a legal settlement and pricing changes, but revenue grew 21.5%, guidance firmed, and analysts and institutions remain bullish on ISRG.

The market has rewarded this biotech for its breakthroughs.

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.

Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.

These companies generate resilient revenues, which help make their stocks less volatile during market downturns.

Tech stocks fell on inflation fears and AI infrastructure concerns while the Dow rose, as MarketBeat analysts review earnings outlooks, sector rotation, and stock picks from the week's top stories.

The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.

These funds can help you weather any storm that might be on the way.

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.

This exchange-traded fund consistently outperforms the S&P 500 thanks to its concentrated portfolio of growth stocks.

International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO.